Lifeboat Foundation

AI has officially entered the field of biology. Meet Evo, a GPT fed millions of microbes instead of words. Read all about it.

Evo marks the next frontier in machine learning by interpreting biological sequence data, including DNA, RNA, and proteins.

According to a new study, researchers may have found a way to get cancer cells to “self-destruct.”

A huge dam in China is changing how long our days are.

New work provides a good view of where the field currently stands.

Physicist Matthias Kling studies photons and the things science can do with ultrafast pulses of X-rays. These pulses last just attoseconds – a billionth of a billionth of a second, Kling says. He uses them to create slo-mo “movies” of electrons moving through materials like those used in batteries and solar cells. The gained knowledge could reshape fields like materials science, ultrafast and quantum computers, AI, and medical diagnostics, Kling tells host Russ Altman on this episode of Stanford Engineering’s The Future of Everything podcast.

Here’s how our bioacoustic foundation model, Health Acoustic Representations (HeAR), may help improve health outcomes for people across India.

Scientists launched a design competition for a massive multi-generational spaceship that could sustain humans on the way to the next star.

SpaceX is preparing to launch the sixth Starship flight test. The window for the launch opens at 4 p.m. local time on Tuesday. The company has confirmed on its website, and X, that it is targeting a potential catch of the Super Heavy test vehicle, if flight parameters allow for it. SpaceX will also try to re-ignite a single Raptor engine in space to demonstrate deorbit capabilities.

Window Opens: November 19th at 4PM CST (22:00 UTC)
Window Closes: November 19th at 4:30PM CST (22:30 UTC)

Continue reading “🔴LIVE: SpaceX Launches Starship Flight 6 (and Catches a Booster)” »

Eradivir, a preclinical biotech company, has developed a patent-pending antiviral therapeutic that reduces lung viral loads of advanced-stage influenza in preclinical studies quicker and more effectively than currently available therapies.

A single intranasal dose of EV25, a bispecific small molecule developed by Eradivir, acts faster than the current standard of care, eliminating the detectable virus within 24 hours. EV25 also has a window of efficacy of 96 hours postinfection, which is broader than the current standard of care.

A research paper titled “Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections” has been published in Proceedings of the National Academy of Sciences.